Marker Therapeutics, Inc. (MRKR)
$0.00+$0.00 (+0.00%) Latest sessionExtended Hours
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
https://www.markertherapeutics.comSEC filings for MRKR on EDGAR
No Form 4 activity for MRKR in the last 90 days.
7 Form 4 filings on record, the earliest from Dec 23, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Norman David Eansor - Director | Grant or award | Stock Option (Right to Buy) | 84,411 | $0.00 | - | |
| Norman David Eansor - Director | Grant or award | Stock Option (Right to Buy) | 137,330 | $0.00 | - | |
| Steve Elms - Director | Grant or award | Stock Option (right to buy) | 84,411 | $0.00 | - | |
| Steve Elms - Director | Grant or award | Stock Option (right to buy) | 137,330 | $0.00 | - | |
| Katharine Knobil - Director | Grant or award | Stock Option (Right to Buy) | 84,411 | $0.00 | - | |
| Katharine Knobil - Director | Grant or award | Stock Option (Right to Buy) | 137,330 | $0.00 | - | |
| Kathryn Penkus Corzo - Director | Grant or award | Stock Option (Right to Buy) | 147,611 | $0.00 | - | |
| Juan Vera - Officer | Grant or award | Employee Stock Option (right to buy) | 250,000 | $0.00 | - | |
| Steve Elms - Director | Open-market purchase | Common Stock | 11,085 | $3.20 | $35K | |
| New Enterprise Associates 16, L.P. | Open-market purchase | Common Stock | 554,250 | $3.20 | $1.77M |
Marker Therapeutics, Inc. (MRKR) has filed no insider reports in the last 90 days. The most recent on record is dated 2025-11-19. The full record for MRKR runs to 7 Form 4 filings, the earliest from 2024-12-23. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of MRKR were filed in the last 90 days. 2 purchases are on record for this company.
No insider sales of MRKR were filed in the last 90 days.
This page tracks MRKR Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add MRKR to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
